Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Academic Licensing Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LVR013
MIFTS: 75

Liver Disease

Categories: Gastrointestinal diseases, Endocrine diseases, Liver diseases, Genetic diseases, Rare diseases, Metabolic diseases
Genes Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Liver Disease

About this section

MalaCards integrated aliases for Liver Disease:

Name: Liver Disease 38 12 15
Liver Diseases 55 43 44 73
Liver Dysfunction 55 73
Liver Failure 55 73
Abnormality of the Liver 29
Disorder of Liver 12
Hepatic Disorder 12
Hepatic Failure 29

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases Metabolic diseases
Anatomical: Gastrointestinal diseases Endocrine diseases Liver diseases
See all MalaCards categories (disease lists)
ICD10: 33


Sources

Summaries for Liver Disease

About this section
MedlinePlus : 43 Your liver is the largest organ inside your body. It helps your body digest food, store energy, and remove poisons. There are many kinds of liver diseases: Diseases caused by viruses, such as hepatitis A, hepatitis B, and hepatitis C Diseases caused by drugs, poisons, or too much alcohol. Examples include fatty liver disease and cirrhosis. Liver cancer Inherited diseases, such as hemochromatosis and Wilson disease Symptoms of liver disease can vary, but they often include swelling of the abdomen and legs, bruising easily, changes in the color of your stool and urine, and jaundice, or yellowing of the skin and eyes. Sometimes there are no symptoms. Tests such as imaging tests and liver function tests can check for liver damage and help to diagnose liver diseases.

MalaCards based summary : Liver Disease, also known as liver diseases, is related to fatty liver disease and alcoholic hepatitis, and has symptoms including abdominal pain, constipation and diarrhea. An important gene associated with Liver Disease is MEG3 (Maternally Expressed 3
LncRNA MEG3 induces cholestatic liver injury by interaction with PTBP1 to facilitate Shp mRNA decay.
Dysfunction Pattern: Regulation), and among its related pathways/superpathways are Metabolism and Folate Metabolism. The drugs Amlodipine and Angiotensin II have been mentioned in the context of this disorder. Affiliated tissues include liver, testes and kidney, and related phenotypes are homeostasis/metabolism and growth/size/body region

Wikipedia : 76 Liver disease (also called hepatic disease) is a type of damage to or disease of the... more...

Sources

Related Diseases for Liver Disease

About this section

Diseases in the Liver Disease family:

Liver Failure, Infantile, Transient Infantile Liver Failure Syndrome 1
Infantile Liver Failure Syndrome 2 Acute Liver Failure

Diseases related to Liver Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 538)
# Related Disease Score Top Affiliating Genes
1 fatty liver disease 34.3 ADIPOQ CYP2E1 GGT1 GPT INS PNPLA3
2 alcoholic hepatitis 33.4 ALB CYP2E1 F2 GPT SLC17A5 TNF
3 nonalcoholic steatohepatitis 33.1 ADIPOQ F2 GPT INS PNPLA3 SLC17A5
4 wilson disease 33.0 ALB F2 GPT
5 cholestasis, progressive familial intrahepatic, 1 32.7 ABCB11 ABCB4 GGT1
6 hepatic vascular disease 32.7 AFP ALB F2
7 cholangitis, primary sclerosing 32.7 ABCB4 DLAT GGT1 GPT
8 sclerosing cholangitis 32.4 ABCB11 ABCB4 ALB GGT1 TNF
9 hepatic encephalopathy 32.4 ALB F2 GPT SLC17A5 TNF
10 cholestasis, progressive familial intrahepatic, 2 32.1 ABCB11 ABCB4
11 acute liver failure 32.1 ALB F2 GPT HGF SLC17A5
12 autoimmune hepatitis 32.0 DLAT F2 GGT1 GPT
13 cholestasis, progressive familial intrahepatic, 3 31.9 ABCB11 ABCB4
14 hepatitis 31.6 AFP F2 GGT1 GPT SLC17A5 TNF
15 portal hypertension 31.4 ALB F2 GPT TNF
16 apnea, obstructive sleep 31.3 ADIPOQ INS TNF
17 hepatic coma 31.2 ALB F2 GPT
18 sleep apnea 31.2 ADIPOQ INS TNF
19 diabetes mellitus, noninsulin-dependent 31.2 ADIPOQ ALB GGT1 GPT INS SLC17A5
20 peritonitis 31.0 ALB F2 TNF
21 cholelithiasis 31.0 ABCB4 ALB GPT
22 alcohol abuse 31.0 CYP2E1 GGT1 GPT SLC17A5
23 alcoholic liver cirrhosis 31.0 AFP ALB CYP2E1 F2 PNPLA3 SLC17A5
24 antipyrine metabolism 30.9 ALB F2
25 primary biliary cirrhosis 30.8 ABCB4 ALB DLAT F2 GGT1
26 arteries, anomalies of 30.8 ADIPOQ ALB F2 INS TNF
27 cholestasis 30.8 ABCB11 ABCB4 F2 GGT1 GPT HSD3B7
28 hepatitis b 30.8 AFP ALB F2 GGT1 GPT SLC17A5
29 hepatitis e 30.7 ALB F2 GPT TNF
30 pyridoxine deficiency 30.7 GPT SLC17A5
31 biliary atresia 30.7 ALB GPT HGF
32 esophageal varix 30.7 AFP ALB F2
33 intrahepatic cholestasis 30.6 ABCB11 ABCB4 ALB GGT1 HSD3B7 SLC17A5
34 schistosomiasis 30.6 ALB F2 TNF
35 inherited metabolic disorder 30.5 ADIPOQ INS PNPLA3 SERPINA1
36 protein-energy malnutrition 30.5 ALB GPT TNF
37 kwashiorkor 30.5 ALB F2 GPT SLC17A5
38 overnutrition 30.4 ADIPOQ INS TNF
39 3-hydroxyacyl-coa dehydrogenase deficiency 30.3 ADIPOQ FAH INS
40 hepatitis a 30.3 AFP ALB F2 GPT SERPINA1 TNF
41 vascular disease 30.3 ADIPOQ ALB F2 INS TNF
42 compartment syndrome 30.3 ALB F2 SLC17A5 TNF
43 cholangitis 30.3 ABCB11 ABCB4 ALB DLAT F2 GGT1
44 eclampsia 30.2 ALB F2 TNF
45 respiratory failure 30.1 ALB SERPINA1 TNF
46 viral hepatitis 30.1 AFP ALB F2 GGT1 GPT SERPINA1
47 constrictive pericarditis 30.0 ALB SERPINA1
48 heart disease 29.9 ADIPOQ ALB F2 INS TNF
49 obstructive jaundice 29.9 ALB F2 GGT1 GPT HGF SLC17A5
50 pre-eclampsia 29.7 ADIPOQ AFP F2 TNF

Comorbidity relations with Liver Disease via Phenotypic Disease Network (PDN):


Active Peptic Ulcer Disease Acute Cystitis
Acute Pancreatitis Deficiency Anemia
Familial Atrial Fibrillation Heart Disease
Hepatic Encephalopathy Ischemic Heart Disease
Protein-Energy Malnutrition

Graphical network of the top 20 diseases related to Liver Disease:



Diseases related to Liver Disease
Sources

Symptoms & Phenotypes for Liver Disease

About this section

UMLS symptoms related to Liver Disease:


abdominal pain, constipation, diarrhea, dyspepsia, heartburn, hepatosplenomegaly, icterus, nausea and vomiting, liver tender, digestive system symptom, gastrointestinal gas, abnormal bruising

MGI Mouse Phenotypes related to Liver Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.13 ABCB11 ABCB4 ADIPOQ AFP ALB CYP2E1
2 growth/size/body region MP:0005378 10.06 ABCB11 ABCB4 ADIPOQ F2 FAH GGT1
3 liver/biliary system MP:0005370 9.93 AFP ALB CYP2E1 FAH HGF HSD3B7
4 mortality/aging MP:0010768 9.8 F2 FAH GGT1 HGF HSD3B7 INS
5 neoplasm MP:0002006 9.17 ABCB4 ADIPOQ AFP ALB CYP2E1 FAH
Sources

Drugs & Therapeutics for Liver Disease

About this section

Drugs for Liver Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1280)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Amlodipine Approved Phase 4,Phase 1 88150-42-9 2162
2
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 68521-88-0, 4474-91-3, 11128-99-7 172198 65143
3
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
4
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
5
Ursodeoxycholic acid Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 128-13-2 31401
6
Entecavir Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 142217-69-4 153941
7
Lamivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 134678-17-4 60825
8
Ethanol Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 64-17-5 702
9
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 657-24-9 14219 4091
10
Morphine Approved, Investigational Phase 4,Phase 3,Phase 1,Not Applicable 57-27-2 5288826
11
Emtricitabine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 143491-57-0 60877
12
Adefovir Dipivoxil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 142340-99-6 60871
13
Gabapentin Approved, Investigational Phase 4,Phase 3 60142-96-3 3446
14
gamma-Aminobutyric acid Approved, Investigational Phase 4,Phase 3,Not Applicable 56-12-2 119
15
Tacrolimus Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 104987-11-3 445643 439492
16
Ezetimibe Approved Phase 4,Phase 2,Phase 1 163222-33-1 150311
17
Orlistat Approved, Investigational Phase 4 96829-58-2 3034010
18
Magnesium oxide Approved Phase 4 1309-48-4 14792
19
Peginterferon alfa-2a Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 198153-51-4 5360545
20
Ribavirin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 36791-04-5 37542
21
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
22
Insulin glulisine Approved Phase 4 207748-29-6
23
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 23994
24
Lactulose Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 4618-18-2 11333
25
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2 44147092
26
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 1994-09-7, 94-09-7 2337
27
Telbivudine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3424-98-4 159269
28
Nitazoxanide Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 55981-09-4 41684
29
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
30
Rifaximin Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 80621-81-4 6436173
31
Erythromycin Approved, Investigational, Vet_approved Phase 4,Phase 1,Not Applicable 114-07-8 12560
32
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
33
Peginterferon alfa-2b Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 99210-65-8, 215647-85-1
34
Menthol Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 2216-51-5 16666
35
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 128794-94-5 5281078
36
Mycophenolic acid Approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 24280-93-1 446541
37
Propranolol Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 525-66-6 4946
38
Nadolol Approved Phase 4,Phase 3,Not Applicable 42200-33-9 39147
39
Carvedilol Approved, Investigational Phase 4,Phase 3,Not Applicable 72956-09-3 2585
40
Spironolactone Approved Phase 4,Phase 2,Phase 3,Not Applicable 1952-01-7, 52-01-7 5833
41
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
42
Amoxicillin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 26787-78-0 33613
43
Azithromycin Approved Phase 4,Phase 2 83905-01-5 55185 447043
44
Cefotaxime Approved Phase 4 63527-52-6 456256 5742673
45
Cefoxitin Approved Phase 4 35607-66-0 441199
46
Ciprofloxacin Approved, Investigational Phase 4,Phase 1,Early Phase 1,Not Applicable 85721-33-1 2764
47
Imipenem Approved Phase 4 74431-23-5, 64221-86-9 104838
48
Vancomycin Approved Phase 4,Phase 3,Not Applicable 1404-90-6 441141 14969
49 Nadroparin Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 9041-08-1
50
Warfarin Approved Phase 4,Phase 3,Phase 2,Not Applicable 81-81-2 6691 54678486

Interventional clinical trials:

(show top 50) (show all 8002)
# Name Status NCT ID Phase Drugs
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4 Lovaza;placebo control
2 Perindopril and Telmisartan for the Treatment of Nonalcoholic Fatty Liver Disease Unknown status NCT02213224 Phase 4 Perindopril;Telmisartan;Amlodipine
3 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
4 Efficacy and Safety of Ursodeoxycholic Acid (UDCA) Added to the DPP-4 Inhibitor in People With Type 2 Diabetes and Chronic Liver Diseases Unknown status NCT01337440 Phase 4 UDCA;Sitagliptin
5 Atorvastatin Versus Vitamin E in Treatment of Non-alcoholic Fatty Liver Disease Unknown status NCT01720719 Phase 4 atorvastatin;Vitamin E
6 Antiviral Therapy in Hepatitis B Virus (HBV)-Related Advanced Liver Disease Patients Unknown status NCT00823550 Phase 4 Entecavir;Lamivudine
7 Effect of Metadoxine on Oxidative Stress in Non-alcoholic Hepatic Steatosis Unknown status NCT02051842 Phase 4 Metadoxine
8 The Orange-III Trial: Optimised Recovery With Movicol® Preoperatively Within an Enhanced Recovery Programme Unknown status NCT01429779 Phase 4 Movicol
9 Intravenous-Morphine and Glucagon-Usage Enhanced MR Cholangiography Unknown status NCT00155376 Phase 4 morphine and glucagon
10 Effect of Probiotics on Gut-Liver Axis of Alcoholic Hepatitis Unknown status NCT02335632 Phase 4 Probiotics (Lacidofil®);Placebo
11 Emtricitabine for Naive Child Chinese Chronic Hepatitis B Patients Unknown status NCT02327676 Phase 4 Emtricitabine
12 Emtricitabine for Naive Chinese Chronic Hepatitis B Patients Unknown status NCT02327663 Phase 4 Emtricitabine
13 Treatment for Alcohol Dependence With Gabapentin Unknown status NCT02771925 Phase 4 Gabapentin 2g/day divided in two doses for 24 weeks;Placebo 2g/day divided in two doses for 24 weeks
14 A Study of Thymoglobulin and Tacrolimus in Liver Transplant Unknown status NCT00564538 Phase 4 anti-thymocyte globulin (rabbit);tacrolimus
15 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4 Ezetimibe
16 Increasing Cure Rate of Hepatitis C Therapy in Obese Hepatitis C Patients Unknown status NCT00871845 Phase 4 Orlistat
17 Emtricitabine for Prevention of Vertical Transmission of HBV in Chinese Pregnant HBsAg Positive Patients Unknown status NCT02327715 Phase 4 Emtricitabine
18 Emtricitabine for Naive Chinese Pregnant Chronic Hepatitis B Patients Unknown status NCT02327702 Phase 4 Emtricitabine
19 Emtricitabine Plus Adefovir Dipivoxil for Naive Chinese HBV Related Cirrhosis Patients Unknown status NCT02327689 Phase 4 Emtricitabine plus adefovir dipivoxil
20 Magnesium in Liver Cirrhosis Unknown status NCT01894867 Phase 4
21 Entecavir for Chronic Hepatitis B Patients With Persistently Normal ALT Unknown status NCT01833611 Phase 4 Entecavir;placebo
22 Telaprevir in Genotype 3 HCV Unknown status NCT02087111 Phase 4 Telaprevir;40 Kd Pegylated interferon alfa 2a;Ribavirin
23 Development of an Imaging Biomarker for Hepatic Fibrosis Using Gadoxetate Disodium Unknown status NCT01783314 Phase 4
24 Various Insulin Regimens for Diabetic Inpatients With Cirrhosis Trial Unknown status NCT01143948 Phase 4 Glargine & Glulisine;Regular insulin;NPH & regular insulin
25 Secondary Prophylaxis of Hepatic Encephalopathy in Cirrhosis Unknown status NCT01178372 Phase 4 Lactulose;Probiotics(VSL#3)
26 Pegylated-Interferon and Ribavirin Plus Metformin in the Treatment of Chronic HCV Infection and Insulin Resistance Unknown status NCT00370617 Phase 4 metformin
27 Treatment of Liver Cirrhosis Due to Hepatitis B Virus With Fuzheng Huayu and Entecavir Unknown status NCT02241590 Phase 4 Entecavir + Placebo;Entecavir + Fuzheng Huayu Tablet
28 Effect of Liraglutide on Fatty Liver Content and Lipoprotein Metabolism Unknown status NCT02721888 Phase 4 Liraglutide;MRI/ MRS (Magnetic Resonance Imaging /Magnetic Resonance Spectroscopy)
29 Traditional Chinese Medicine Combined With Entecavir to Treat Refractory Liver Fibrosis in Liver Cirrhosis Due to HBV Unknown status NCT02241616 Phase 4 Entecavir+Fuzheng Huayu+TCM Granule
30 Efficacy of Telbivudine With or Without add-on Tenofovir According to Roadmap Strategy Compare With Entecavir Unknown status NCT01588912 Phase 4 Telbivudine;Tenofovir;Entecavir
31 Randomized Comparison of Two Albumin Administration Schedules for Spontaneous Bacterial Peritonitis (SBP) Unknown status NCT00761098 Phase 4 Standard Care;Experimental
32 Trial Comparing the Efficacy, Tolerability and Safety Between Three Arms in Treatment of HCV in Egyptian Population Unknown status NCT01896609 Phase 4 Bon one in Arm 3;Xerovirinc in Arm 2;Ribavirin in Arm 1
33 HIV Persistence and Viral Reservoirs Unknown status NCT01025427 Phase 4 Raltegravir, tenofovir/emtricitabine
34 Safety of Acamprosate for Alcohol Dependence in the Elderly: An Open-Label Study (SAFADIE) Unknown status NCT00655967 Phase 4 Acamprosate (Campral);Acamprosate
35 Rifaximin Versus Lactulose in Renal Failure Unknown status NCT00748904 Phase 4 Rifaximin;Lactulose
36 Erythromycin Treatment for Readthrough of APC Gene Stop Codon Mutations in Familial Adenomatous Polyposis Unknown status NCT02175914 Phase 4 Erythromycin
37 Crossover of Higher Dose Statins in Patients With Low High-density Lipoproteins Cholesterol (HDLc) Unknown status NCT00736463 Phase 4 Simvastatin;Atorvastatin 80 mg
38 Metformin for Weight Control in Adolescents Taking Atypical Antipsychotics Unknown status NCT00845936 Phase 4 Metformin
39 A Pilot Study to Treat Patients With Chronic Hepatitis C Virus (HCV) Genotype 1 and End-Stage Renal Disease (ESRD) Unknown status NCT01731301 Phase 4 Ribavirin;Peginterferon;Boceprevir
40 Assessment of Coagulation Abnormalities in Acute on Chronic Liver Failure Patients Using Thromboelastography Unknown status NCT02757170 Phase 4
41 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4 Metformin
42 Endoesophageal Cryotherapy For Ablating Barrett's Esophagus and Early Stage Esophageal Cancer Unknown status NCT00628784 Phase 4
43 Complex Imaging Assessment of Steatosis Unknown status NCT02669641 Phase 4
44 TO Compare the Triple Drug Therapy and Dual Therapy . Unknown status NCT02075242 Phase 4 Mycophenolate Mofetil;Tacrolimus
45 A Trial of EVL\GVS Alone vs. EVL\GVS Combined Propranolol Unknown status NCT01298284 Phase 4 propranolol
46 Endoscopic Cyanoacrylate Obliteration vs. Nadolol Treatment in the Prevention of Gastric Variceal Rebleeding Unknown status NCT00567216 Phase 4 Nadolol
47 Rifaximin Predicts the Complications of Decompensated Cirrhosis Unknown status NCT02074280 Phase 4 rifaximin
48 Telbivudine Renoprotective Effect in Patients With the HBV-related Liver Cirrhosis: a Randomized Controlled Trial Unknown status NCT01799486 Phase 4 Telbivudine;Enecavir;Adefovir
49 Telbivudine Renoprotective Effect in Patients With HBV-related Liver Cirrhosis Unknown status NCT01693679 Phase 4 Telbivudine, Lamivudine, Adefovir ,Enecavir
50 RCT of Carvedilol Versus Variceal Band Ligation in the Primary Prophylaxis of Oesophageal Variceal Haemorrhage Unknown status NCT01070641 Phase 4 Carvedilol

Search NIH Clinical Center for Liver Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Liver Disease cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Liver Disease:
Adult stem cell therapy for liver insufficiency
Bone marrow-derived mesenchymal stem cells for treatment of liver failure
Embryonic/Adult Cultured Cells Related to Liver Disease:
Peripheral blood-derived hematopoietic stem cells PMIDs: 18181952 16556705 22121493
Bone marrow-derived mesenchymal stem cells (family)

Cochrane evidence based reviews: liver diseases

Sources

Genetic Tests for Liver Disease

About this section

Genetic tests related to Liver Disease:

# Genetic test Affiliating Genes
1 Hepatic Failure 29
2 Abnormality of the Liver 29
Sources

Anatomical Context for Liver Disease

About this section

MalaCards organs/tissues related to Liver Disease:

41
Liver, Testes, Kidney, T Cells, Bone, Lung, Bone Marrow
Sources

Publications for Liver Disease

About this section

Articles related to Liver Disease:

(show top 50) (show all 4326)
# Title Authors Year
1
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis. ( 29958825 )
2018
2
Obestatin protects and reverses nonalcoholic fatty liver disease and its associated insulin resistance in rats via inhibition of food intake, enhancing hepatic adiponectin signaling, and blocking ghrelin acylation. ( 29429367 )
2018
3
Impact of liver volume on polycystic liver disease-related symptoms and quality of life. ( 29435317 )
2018
4
Simultaneous quantification of hepatic MRI-PDFF and R2* in a rabbit model with nonalcoholic fatty liver disease. ( 29934919 )
2018
5
Chicory (Cichorium intybus L.) polysaccharides attenuate high-fat diet induced non-alcoholic fatty liver disease via AMPK activation. ( 29964102 )
2018
6
Taurine attenuates the development of hepatic steatosis through the inhibition of oxidative stress in a model of nonalcoholic fatty liver disease in vivo and in vitro. ( 29946793 )
2018
7
Nonalcoholic Fatty Liver Disease: Time to Take the Bull by the Horns. ( 29963461 )
2018
8
Role of genetic and metabolism in non-alcoholic fatty liver disease. ( 29442484 )
2018
9
Effects of isomaltulose on insulin resistance and metabolites in patients with nona89alcoholic fatty liver disease: A metabolomic analysis. ( 29956790 )
2018
10
Noninvasive Quantitative Detection Methods of Liver Fat Content in Nonalcoholic Fatty Liver Disease. ( 29951367 )
2018
11
PNPLA3: A Determinant of Response to Low-Fructose Diet in Nonalcoholic Fatty Liver Disease. ( 29452087 )
2018
12
Quantification of hepatic perfusion and hepatocyte function with dynamic gadoxetic acid-enhanced MR imaging in patients with chronic liver disease. ( 29440620 )
2018
13
Multiparametric MRI for early detection of diffuse liver disease: an interview with David Breen. ( 29318905 )
2018
14
A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis. ( 29942422 )
2018
15
Dysbiosis of oral microbiota and its association with salivary immunological biomarkers in autoimmune liver disease. ( 29969462 )
2018
16
Role of palliative resection of the primary pancreatic neuroendocrine tumor in patients with unresectable metastatic liver disease: a systematic review and meta-analysis. ( 29503572 )
2018
17
Exploring the relationship between nonalcoholic fatty liver disease and pancreatic cancer by computed tomographic survey. ( 29235054 )
2018
18
Editorial: the role of colonic inflammation in the progression of liver disease in primary sclerosing cholangitis-Authors' reply and Letter: the effects of colectomy prior to the diagnosis of primary sclerosing cholangitis on prognosis may have been overestimated. ( 29314129 )
2018
19
Model for end-stage liver disease predicts mortality after pericardiectomy for constrictive pericarditis. ( 29893857 )
2018
20
Statin Use In Cirrhosis from Fatty Liver Disease. ( 29443384 )
2018
21
Liver disease in patients with cystic fibrosis. ( 29438119 )
2018
22
Urea cycle dysregulation in non-alcoholic fatty liver disease. ( 29981428 )
2018
23
Unexplained chronic liver disease in Ethiopia: a cross-sectional study. ( 29439653 )
2018
24
THE USE OF MELD SCORE (MODEL FOR END-STAGE LIVER DISEASE) AND DERIVATIVES IN CARDIAC TRANSPLANTATION. ( 29972398 )
2018
25
Open-label study of ademetionine for the treatment of intrahepatic cholestasis associated with alcoholic liver disease. ( 29431335 )
2018
26
Practical Dietary Recommendations for the Prevention and Management of Nonalcoholic Fatty Liver Disease in Adults. ( 29438460 )
2018
27
Presentation and prognosis of liver disease in alpha-1 antitrypsin deficiency. ( 29768056 )
2018
28
Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential. ( 29427497 )
2018
29
Noninvasive Assessment of Portal Hypertension in Advanced Chronic Liver Disease: An Update. ( 29977287 )
2018
30
Validation of simple indexes for nonalcoholic fatty liver disease in western China: a retrospective cross-sectional study. ( 29434074 )
2018
31
High Prevalence of Liver Fibrosis Among European Adults with Unknown Liver Disease. A Population-Based Study. ( 29452268 )
2018
32
Pharmacotherapies for fatigue in chronic liver disease (CLD): a systematic review and meta-analysis (protocol). ( 29444700 )
2018
33
The protective effect of fish oil lipid emulsions on intestinal failure-associated liver disease in a rat model of short-bowel syndrome. ( 29039050 )
2018
34
Genetic variations in toll-like receptors 7 and 8 modulate natural hepatitis C outcomes and liver disease progression. ( 28752959 )
2018
35
Liver transplantation in adults with liver disease due to common variable immunodeficiency leads to early recurrent disease and poor outcome. ( 29156507 )
2018
36
Personalized therapy when tackling nonalcoholic fatty liver disease: a focus on sex, genes, and drugs. ( 29969922 )
2018
37
Risk factors and metabolic abnormality of patients with non-alcoholic fatty liver disease: Either non-obese or obese Chinese population. ( 29428103 )
2018
38
The Influence of Gut Microbial Metabolism on the Development and Progression of Non-alcoholic Fatty Liver Disease. ( 29956209 )
2018
39
Normal serum alanine aminotransferase and non-alcoholic fatty liver disease among Korean adolescents: a cross-sectional study using data from KNHANES 2010-2015. ( 29976192 )
2018
40
Correction: Prospective comparison among transient elastography, supersonic shear imaging, and ARFI imaging for predicting fibrosis in nonalcoholic fatty liver disease. ( 29944727 )
2018
41
Changes in inflammatory factors and prognosis of patients complicated with non-alcoholic fatty liver disease undergoing coronary artery bypass grafting. ( 29434690 )
2018
42
Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease. ( 29956204 )
2018
43
CT Scan Is Still a Valuable Tool to Assess Hepatic Encephalopathy Pathophysiology in Both Acute and Chronic Liver Diseases. ( 29912129 )
2018
44
Future therapy for non-alcoholic fatty liver disease. ( 29427492 )
2018
45
Evaluation of nonalcoholic fatty liver disease using magnetic resonance in obese children and adolescents. ( 29438686 )
2018
46
Non-alcoholic fatty liver disease severity is modulated by transglutaminase type 2. ( 29449533 )
2018
47
Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease. ( 29368124 )
2018
48
Peliosis Hepatis Simulating Metastatic Liver Disease on FDG PET/CT. ( 29659400 )
2018
49
Value of Serum Zinc in Diagnosing and Assessing Severity of Liver Disease in Children with Wilson Disease. ( 29668570 )
2018
50
Hepatitis A and hepatitis B vaccination coverage among adults with chronic liver disease. ( 29395521 )
2018